Linking Microbial Genotoxins to Tumor Mutational Signatures: A Host–Microbiome Multi-Omics Study Design

Meta Intent: A practical framework for combining matched tumor–normal WGS, tumor transcriptomics, fecal shotgun metagenomics, and exposure metadata to evaluate microbial genotoxin hypotheses without treating current microbial detection as proof of historical causation.

Microbiome studies often start with a tempting observation: a potentially harmful bacterial taxon or toxin gene is enriched in a cohort with cancer. The difficulty begins when that observation is asked to carry more meaning than the data can support. A stool sample describes a microbial community at collection. A tumor genome records mutations accumulated across the lineage that gave rise to the sampled lesion. Tumor RNA describes a tissue state at resection. These are not interchangeable readouts, and they do not operate on the same clock.

That distinction is especially important for microbial genotoxins. A genotoxin can damage epithelial DNA during a short exposure window, while its induced mutations persist as the affected clone expands. By diagnosis, the source strain may have changed, fallen below detection, or disappeared. Conversely, a toxin-gene-positive strain detected in stool may never have contacted the relevant epithelial niche or produced biologically meaningful amounts of toxin. A defensible project therefore needs more than a correlation between taxon abundance and a tumor feature. It needs a pre-specified evidence chain.

Colibactin is the best-developed example for this kind of design. The pks island found in some Enterobacteriaceae encodes a pathway associated with the genotoxin colibactin; in colorectal tumor genomes, the corresponding mutation patterns are commonly represented by SBS88 and ID18. This does not mean that every microbial toxin has an equally specific signature. Enterotoxigenic Bacteroides fragilis, for example, has strong mechanistic relevance in experimental colorectal tumor models but has not been shown to create an analogous unique mutational signature. The practical lesson is simple: use colibactin as the reference case for evidence integration, and keep candidate toxins without a validated genomic footprint in a separate, hypothesis-generating tier.

This article outlines a study architecture for research teams that want to link microbial genotoxin hypotheses to tumor genomics without overstating causality. It centers on paired tumor–normal sequencing, host RNA-seq, fecal shotgun metagenomics, exposure-aware metadata, and targeted escalation when the data disagree.

Figure 1. Three evidence clocks distinguish the historical tumor-genome scar from current microbial potential and current host transcriptional state.

Start With the Claim You Want the Study to Support

The first design decision is not sequencing depth. It is the strength of the claim the study should be able to make. “Microbes are associated with the tumor” and “a microbial genotoxin caused this mutation process” require fundamentally different evidence. If this distinction is left vague, a study can collect impressive data yet still produce an answer that is impossible to interpret.

Use four claim levels

1. Association: a toxin gene, microbial strain, or microbial community feature is more common in tumors carrying a defined genomic feature.
2. Compatibility: a signature, microbial functional potential, host pathway state, and exposure timeline point in a biologically coherent direction.
3. Source attribution: the data support a particular strain or gene island as a plausible local source of the proposed genotoxic exposure.
4. Mechanistic causation: an appropriately controlled model reproduces the relevant DNA lesion or mutational pattern.

Most cross-sectional human cohorts can credibly address the first two levels. Localized tissue sampling, repeated samples, and strain-resolved sequencing can strengthen source attribution. Mechanistic causation normally requires a controlled system, such as a repeated exposure experiment followed by clonal expansion and sequencing. Treating all four levels as if they were reachable from one stool sample is the most common interpretive failure in this field.

Write the primary endpoint before sample collection. For a colibactin-focused study, that may be a pre-specified SBS88/ID18 classification or continuous signature exposure estimate. Secondary endpoints can include pks-island coverage, strain assignment, host DNA-damage pathway scores, and location-specific metadata. This hierarchy prevents the project from selecting its main result after inspecting dozens of possible taxa, pathways, and mutation patterns.

Build a Matched Specimen Set Rather Than a Loose Collection of Omics

The minimum defensible specimen set contains tumor DNA, matched normal DNA, tumor RNA, and a stool sample collected within a documented time window. In practice, the quality of the links between samples matters as much as the quality of each assay. Each aliquot should have a sample identifier, collection time, storage history, pre-treatment status, anatomical site, extraction batch, library batch, and sequencing batch recorded in the same metadata table.

The core set

Whole Genome Sequencing of tumor and matched normal material creates the somatic mutation catalogue required for a reliable signature analysis. Matched blood is often the cleanest normal comparator, although another carefully qualified non-tumor source may be appropriate for a defined research protocol. The key is to avoid asking a tumor-only mutation callset to distinguish somatic events from germline variants and technical noise on its own.

Use RNA-Seq on the same tumor region or a documented adjacent section to characterize host-state programs. RNA should not be treated as a substitute for DNA: it adds context about pathways and cell composition, rather than reconstructing the historical mutation process. For stool, Metagenomic Shotgun Sequencing provides the functional resolution needed to evaluate toxin-gene content, whereas marker-gene surveys are usually insufficient for strain-level or gene-island questions.

Where the project can support it, add adjacent normal mucosa, mucosal brushings, or tumor-associated material. This is not a luxury add-on. Stool is a useful, repeatable luminal sample, but it only partly reflects the microbes at the mucosal or tumor interface. A local sample can help separate a generalized fecal signal from a potentially relevant local exposure context.

Randomize extraction and library preparation across the anticipated signature and microbial-status groups rather than processing one group first. Include extraction blanks, library blanks, and a microbial positive-control material in the metagenomic run. For tumor DNA and RNA, keep matched specimens together in the tracking system while distributing them across practical processing batches. These steps do not eliminate biological variability, but they make it less likely that a batch label is later mistaken for a host–microbe relationship.

Figure 2. Matched tumor, normal, RNA, stool, mucosal, and metadata collection architecture for a microbial-genotoxin study.

Collect stool before the microbial baseline is disturbed

Stool timing deserves its own protocol line. Record whether collection occurred before bowel preparation, antibiotic exposure, surgery, systemic treatment, or a major dietary intervention. A post-preparation or post-surgical stool sample can still be valuable, but it should not be labeled as a baseline exposure sample. If longitudinal sampling is feasible, a pre-treatment sample plus one or more later samples is more informative than a single point measurement, particularly when the biological question concerns persistence of a candidate strain.

Use Tumor–Normal WGS to Measure the Genomic Scar, Not to Guess the Microbe

A mutational signature is a pattern in a catalogue of somatic changes. It is not a barcode that names a bacterium. The WGS workflow should therefore begin with conventional tumor-genome discipline: assess tumor content, DNA integrity, duplication, coverage balance, and contamination; call somatic single-nucleotide variants and indels against a matched normal; and retain a traceable record of filtering decisions. Variant Calling is not a generic upstream task here. Reference build, caller choice, low-allele-fraction handling, and filtering criteria can alter the final mutation spectrum.

Fit signatures with uncertainty, not with a binary button

For colibactin, analyze SBS88 and ID18 as related but distinct signals. SBS88 is a base-substitution pattern; ID18 captures a short-indel pattern with characteristic sequence context. A sample can have an interpretable signal in one catalogue but not the other because mutation count, coverage, tumor purity, and indel-calling sensitivity differ. The report should retain the raw number of SBS and indel events, the modeled exposure, reconstruction quality, and a confidence interval or resampling-based stability result.

Low mutation counts are a major practical constraint. A signature can be overfit when the catalogue is small, and similar or broad signatures can redistribute contributions depending on the fitting method. For this reason, reference fitting should be restricted to a biologically reasonable signature set, with pre-defined sensitivity analyses. If the result moves substantially after changing the fitting method, tumor-purity threshold, or variant filter, it should be described as uncertain rather than promoted as a definitive positive.

When whole-genome analysis is not feasible, targeted panels may support a focused exploratory question, but they are less suitable for complete SBS and indel attribution. A strategy that begins with a limited panel and escalates signature-positive or indeterminate cases to WGS can be useful, provided that the two evidence levels are not reported as equivalent.

Predefine what a negative or indeterminate WGS result will mean before data generation. For example, a tumor with adequate purity and mutation burden but no stable SBS88 or ID18 contribution can be reported as lacking genomic support for this specific exposure hypothesis in the sampled lineage. It should not be recast as evidence that no microbial influence occurred. This distinction protects the study from both overcalling weak signatures and overstating a null result.

Separate biological uncertainty from technical uncertainty

A low or unstable signature estimate can arise for several reasons that should not be pooled into one “negative” label. The tumor may truly lack that mutational process. The exposure may have occurred in only a small ancestral subclone. Tumor content may be too low for reliable somatic calling. FFPE damage or a poorly balanced normal sample may inflate a competing pattern. A project report should separate these explanations through a short technical adjudication table: mutation count, tumor purity, normal-sample quality, indel callability, reconstruction error, and signature stability under alternative filters.

This separation helps a team choose the next assay rationally. A technically indeterminate sample may benefit from re-extraction, macrodissection, deeper genome sequencing, or a different specimen block. A biologically discordant sample may instead need a closer look at sample timing or a local microbial specimen. Without that distinction, expensive sequencing can be repeated when the actual issue is an unanswerable exposure question, or an interesting biological discordance can be discarded as if it were a laboratory failure.

Figure 3. Tumor–normal WGS workflow from somatic variant calling to SBS88 and ID18 fitting with uncertainty checks.

Use Host Transcriptomics as Compatibility Evidence

Host transcriptomics can answer a different question: does the sampled tumor region show a biological state that is compatible with the proposed host–microbe interaction? A practical analysis begins with pre-specified gene-set-level readouts, not a hunt for a single “colibactin gene.” DNA damage response, replication stress, cell-cycle control, epithelial barrier remodeling, inflammatory signaling, and immune-cell composition can all be relevant. None is unique to a microbial genotoxin.

That limitation is productive if it is built into the design. Rather than writing that a microbial gene “caused” a transcriptional change, test whether a tumor with a defined genomic scar and microbial functional evidence also shows concordant pathway-level features. Use tumor purity estimates and deconvolution to keep shifts in stromal or immune content from being misread as tumor-cell expression changes. If paired adjacent tissue is available, analyze it as a contextual comparator, not merely as a leftover control.

When spatial context matters, 10x Spatial Transcriptome Sequencing Service can help distinguish epithelial, immune, and stromal compartments at the host–microbe interface. It is most useful when the study asks where a response is localized, not when used as a decorative expansion of a bulk RNA-seq study.

Measure Genotoxic Potential in Stool at Gene-Island and Strain Resolution

For a toxin encoded by a multi-gene locus, one marker is rarely enough. A practical pks analysis asks whether reads support multiple genes across the island, whether coverage is coherent across the locus, whether the signal can be assigned to a plausible microbial genome, and whether the observed sequence appears intact. A single short alignment can arise from shared sequence, incomplete assembly, or contamination; it should be treated as a screening clue, not an exposure measurement.

Report breadth and depth of coverage separately. Breadth asks how much of the locus is represented. Depth asks how strongly it is represented. Both should be interpreted relative to sequencing depth, read quality, host-read depletion, and the abundance of the proposed carrier organism. If the project needs to resolve the strain architecture or examine the wider genomic background of a candidate isolate, Microbial Whole Genome Sequencing can provide a more direct route than assigning short stool reads to a reference strain with false precision.

Relative abundance alone can also be misleading when total microbial load changes across collection conditions. When the research question concerns the absolute burden of a candidate carrier or toxin-gene locus, Absolute Metagenomic Sequencing Service can complement compositional analysis with a more interpretable estimate of copy-number change. It does not establish past epithelial exposure, but it can distinguish an apparent relative increase from a change in measured microbial burden.

Gene presence is still not gene activity. If the central question is whether the pathway is active in the sampled community, add Metatranscriptomic Sequencing as a targeted escalation. It can test whether reads map to expressed pathway genes, although RNA stability, library composition, and low organism abundance remain important limitations. A negative metatranscriptomic result cannot erase an earlier exposure; a positive result cannot alone prove that tumor mutations were induced by that exposure.

Figure 4. pks island evidence ladder from a single marker read to complete strain-resolved and expression-supported detection.

Make the Exposure Timeline a First-Class Dataset

A careful multi-omics study treats timing as data, not as a paragraph in the methods. The tumor genome may contain a scar from a remote exposure. The fecal metagenome is a near-current sample. RNA-seq captures the tissue at collection. Between those layers sit antibiotics, bowel preparation, surgery, treatment, diet, inflammation, disease progression, and sample handling. If the project does not track these events, it cannot distinguish a plausible biological mismatch from a laboratory inconsistency.

Build an exposure table with case-level variables such as tumor location, collection date and time, treatment status, bowel-preparation timing, recent antibiotic classes and dates, major medications, sample stabilization method, storage interval, smoking status, dietary pattern variables, and any available history relevant to the project question. Use the same table to plan covariates before model fitting. The goal is not to collect every imaginable variable; it is to capture the variables that can change microbial composition, host state, or sample comparability.

It is also useful to predefine discordant outcomes. A tumor may carry a credible SBS88/ID18 signal while stool is currently pks-negative. That pattern is compatible with a past exposure and should trigger review of timing, mucosal evidence, and sequencing sensitivity. Conversely, a current pks-positive stool sample with no signature may reflect insufficient exposure, a nonfunctional island, a recent colonization event, or a tumor lineage whose relevant cells were never exposed. Treating either pattern as an automatic failure wastes some of the most informative cases in the cohort.

Figure 5. Exposure-aware timeline aligning early mutational scarring with current stool, tumor RNA, treatment, and sample-processing events.

Integrate Modalities Only After Each One Passes Its Own QC

Multi-omics integration is most credible when it comes last. First complete the WGS QC and signature analysis, RNA-seq QC and pathway scoring, metagenomic QC and gene-island assessment, and metadata audit independently. Only then should the project build cross-modal models. This prevents one attractive result from nudging analysts to loosen standards in another layer.

At the case level, create a compact evidence matrix with five columns: genomic scar, microbial functional potential, host-state compatibility, exposure timing, and local spatial support. A Multi-Omics Service is most valuable when the resulting integration plan remains interpretable at this level. A complex latent-factor model may be useful for discovery, but it should not replace transparent modality-specific evidence.

For confirmatory analyses, define one primary association, such as whether complete pks-island evidence is enriched among tumors with a pre-specified SBS88/ID18 pattern. Then add covariates that were justified before results were known. Metagenomic data are compositional, so abundance analysis should be handled accordingly. Include a discovery/validation split whenever cohort size permits, and report negative controls: non-genotoxic gene clusters, unrelated signatures, and technical blanks where appropriate.

Do not use a single correlation heatmap as the integration result. It will privilege abundant features, hide shared batch effects, and make it easy to select a visually attractive association after the fact. Instead, retain modality-specific outputs alongside the integrated model: a variant catalogue and signature report for WGS, pathway score table for RNA-seq, locus-coverage report for metagenomics, and a collection-time audit for metadata. This makes the study reviewable by the genomics, microbiome, and pathology teams independently.

For cohorts with heterogeneous tumor sites or treatment histories, stratification is often more informative than forcing one global model. Colon and rectal tumors, for example, should not automatically be combined if their sample collection, local ecology, and molecular backgrounds differ. Likewise, a model trained on treatment-naive specimens should not be assumed to describe post-treatment samples. The most useful outcome may be a carefully bounded subgroup finding rather than a broad but unstable conclusion.

A practical evidence-grade system

• Grade 0: taxonomic association only; no credible toxin-gene or signature evidence.
• Grade 1: a credible tumor mutational footprint; current microbial evidence absent or unavailable.
• Grade 2: mutational footprint plus coherent current stool gene-island evidence.
• Grade 3: Grade 2 plus localized mucosal or tumor-associated evidence, repeated sampling, or strain-level reinforcement.
• Grade 4: controlled experimental replication of the relevant DNA-damage and mutation process.

Grades should describe the evidence package, not the biological importance of a case or sample. A Grade 1 case may be more informative than a weak Grade 2 case if WGS confidence is high and the stool sample was collected years later. The system is intended to stop language from outrunning the study design.

Figure 6. Evidence-grading matrix for interpreting microbial genotoxin hypotheses from association to controlled mechanistic replication.

Escalate Selectively With Local Sampling or Controlled Models

Not every cohort needs every assay. Escalation should be driven by an explicit uncertainty. If stool and tumor data conflict, add a local mucosal sample when feasible. If the pks locus is fragmented in short-read data, consider strain-resolved assembly or isolate sequencing. If gene presence is strong but pathway activity remains the central uncertainty, use metatranscriptomics. If the biological objective is to establish mechanism rather than association, move to a controlled model rather than adding more correlation analyses.

For the latter question, Organoids Sequencing Service can support repeated-exposure designs in which defined microbial states or products are compared with matched negative controls, followed by clonal sequencing. The critical features are isogenic or otherwise well-matched controls, pre-defined exposure duration, recovery or expansion interval, clone-selection logic, stopping rules, independent replicates, and a pre-specified comparison to the tumor signature of interest. These timings must be established for the specific model and candidate factor; there is no universal exposure window. An organoid experiment can test whether a candidate exposure is capable of generating a compatible pattern; it does not retroactively prove that the same event occurred in the original lesion.

A Field-Ready Workflow for Project Teams

1. Write the primary claim and evidence grade the study is intended to reach.
2. Define the matched tumor, normal, RNA, stool, and optional local-microbiome specimen set.
3. Lock the collection window before bowel preparation, antibiotics, or treatment whenever possible.
4. Run assay-specific QC before cross-modal analysis.
5. Fit tumor signatures with raw counts, confidence measures, and sensitivity analyses.
6. Assess toxin-gene loci using completeness, coverage, and strain context rather than a single marker.
7. Use RNA-seq for pathway compatibility and cell-composition-aware context.
8. Integrate results in a case-level evidence matrix and pre-specified statistical model.
9. Classify concordant, discordant, and indeterminate cases instead of forcing a binary answer.
10. Escalate only the cases where local sampling, functional RNA, or a controlled model would resolve a defined uncertainty.

The most useful deliverable is not a list of “microbes associated with cancer.” It is a traceable report that shows which claims are supported, which remain plausible but unproven, and exactly what additional experiment would change the conclusion. That is the difference between a multi-omics data collection exercise and a study capable of guiding the next research decision.

Frequently Asked Questions

For research use only. Not for diagnostic procedures, clinical decision-making, patient stratification, therapeutic selection, or clinical trials.

References:

1. Terlouw D, et al. Enrichment of colibactin-associated mutational signatures in unexplained colorectal polyposis patients. BMC Cancer. 2024;24:104.
2. Zou S, et al. Multi-omic profiling reveals associations between the gut microbiome, host genome and transcriptome in patients with colorectal cancer. Journal of Translational Medicine. 2024;22:175.
3. Kneis B, et al. Colon cancer microbiome landscaping: differences in right- and left-sided colon cancer and a tumor microbiome–ileal microbiome association. International Journal of Molecular Sciences. 2023;24:3265.
4. Allen J, et al. Colon tumors in enterotoxigenic Bacteroides fragilis-colonized mice do not display a unique mutational signature but instead possess host-dependent alterations in the APC gene. Microbiology Spectrum. 2022;10:e01055-22.
5. Suresh A, et al. Evolutionary dynamics based on comparative genomics of pathogenic Escherichia coli lineages harboring polyketide synthase island. mBio. 2021;12:e03634-20.

Related Services